Semaglutide 1 mg pharmacokinetic equivalence assessed between DV3372 and PDS290 pen-injector devices

For individuals managing Type 2 Diabetes Mellitus (T2DM), consistent and reliable drug delivery is paramount for achieving optimal glycemic control and minimizing complications. Semaglutide, a potent GLP-1 receptor agonist, is a cornerstone therapy, but its efficacy relies on predictable systemic exposure. While the drug itself is well-characterized, the performance of different injection devices can subtly influence drug absorption kinetics, potentially impacting patient experience and therapeutic outcomes. Ensuring bioequivalence across various delivery systems is crucial for patient safety, adherence, and regulatory approval, addressing a key gap in understanding real-world drug performance.

This was a randomized, quadruple-blinded, Phase 1 clinical trial involving 54 participants with Type 2 Diabetes Mellitus. The study aimed to compare the pharmacokinetic profiles of semaglutide 1 mg when administered subcutaneously (SC) using either the DV3372 device or the PDS290 semaglutide pen-injector. Participants received escalating doses of semaglutide: 0.25 mg on days 1 and 8, 0.5 mg on days 15 and 22, and finally 1.0 mg on day 29. All injections were given in the morning after an overnight fast of at least 8 hours. The primary endpoint was to compare blood concentration levels and other pharmacokinetic properties of semaglutide between the two delivery devices.

The provided abstract describes the design and objectives of the study rather than presenting specific results or numerical findings. Therefore, no quantitative data, p-values, or fold-changes from the trial's outcome are available within this record. The core objective was to establish bioequivalence between the two semaglutide delivery devices. The study aimed to demonstrate that: Similar levels of semaglutide in the blood would be achieved when using either the DV3372 device or the PDS290 semaglutide pen-injector. This comparison typically involves assessing key pharmacokinetic parameters such as area under the curve (AUC), maximum plasma concentration (Cmax), and time to maximum concentration (Tmax). The researchers also intended to evaluate the overall performance and usability of the injection tools. Without the full study report, specific data on AUC ratios, Cmax equivalence, or statistical significance (p-values) regarding the similarity of the devices cannot be reported here. The trial's completion status indicates that these data have been collected and analyzed by the sponsor.